Literature DB >> 23108553

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.

Alline Cristina Campos1, Fabricio Araújo Moreira, Felipe Villela Gomes, Elaine Aparecida Del Bel, Francisco Silveira Guimarães.   

Abstract

Cannabidiol (CBD) is a major phytocannabinoid present in the Cannabis sativa plant. It lacks the psychotomimetic and other psychotropic effects that the main plant compound Δ(9)-tetrahydrocannabinol (THC) being able, on the contrary, to antagonize these effects. This property, together with its safety profile, was an initial stimulus for the investigation of CBD pharmacological properties. It is now clear that CBD has therapeutic potential over a wide range of non-psychiatric and psychiatric disorders such as anxiety, depression and psychosis. Although the pharmacological effects of CBD in different biological systems have been extensively investigated by in vitro studies, the mechanisms responsible for its therapeutic potential are still not clear. Here, we review recent in vivo studies indicating that these mechanisms are not unitary but rather depend on the behavioural response being measured. Acute anxiolytic and antidepressant-like effects seem to rely mainly on facilitation of 5-HT1A-mediated neurotransmission in key brain areas related to defensive responses, including the dorsal periaqueductal grey, bed nucleus of the stria terminalis and medial prefrontal cortex. Other effects, such as anti-compulsive, increased extinction and impaired reconsolidation of aversive memories, and facilitation of adult hippocampal neurogenesis could depend on potentiation of anandamide-mediated neurotransmission. Finally, activation of TRPV1 channels may help us to explain the antipsychotic effect and the bell-shaped dose-response curves commonly observed with CBD. Considering its safety profile and wide range of therapeutic potential, however, further studies are needed to investigate the involvement of other possible mechanisms (e.g. inhibition of adenosine uptake, inverse agonism at CB2 receptor, CB1 receptor antagonism, GPR55 antagonism, PPARγ receptors agonism, intracellular (Ca(2+)) increase, etc.), on CBD behavioural effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23108553      PMCID: PMC3481531          DOI: 10.1098/rstb.2011.0389

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  130 in total

1.  Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test.

Authors:  Fabrício A Moreira; Daniele C Aguiar; Francisco S Guimarães
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-07-31       Impact factor: 5.067

Review 2.  TRP channels: a TR(I)P through a world of multifunctional cation channels.

Authors:  Bernd Nilius; Thomas Voets
Journal:  Pflugers Arch       Date:  2005-07-13       Impact factor: 3.657

3.  Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus.

Authors:  E M Rock; D Bolognini; C L Limebeer; M G Cascio; S Anavi-Goffer; P J Fletcher; R Mechoulam; R G Pertwee; L A Parker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

4.  Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia.

Authors:  Anand Gururajan; David Alan Taylor; Daniel Thomas Malone
Journal:  Behav Brain Res       Date:  2011-03-31       Impact factor: 3.332

5.  Cannabidiol-induced intracellular Ca2+ elevations in hippocampal cells.

Authors:  Alison J Drysdale; Duncan Ryan; Roger G Pertwee; Bettina Platt
Journal:  Neuropharmacology       Date:  2005-12-28       Impact factor: 5.250

6.  Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats.

Authors:  Eric Murillo-Rodríguez; Diana Millán-Aldaco; Marcela Palomero-Rivero; Raphael Mechoulam; René Drucker-Colín
Journal:  FEBS Lett       Date:  2006-07-10       Impact factor: 4.124

7.  Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol.

Authors:  Paolo Fusar-Poli; Paul Allen; Sagnik Bhattacharyya; José A Crippa; Andrea Mechelli; Stefan Borgwardt; Rocio Martin-Santos; Marc L Seal; Colin O'Carrol; Zerrin Atakan; Antonio W Zuardi; Philip McGuire
Journal:  Int J Neuropsychopharmacol       Date:  2009-09-24       Impact factor: 5.176

8.  Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus.

Authors:  Anikó Ludányi; Loránd Eross; Sándor Czirják; János Vajda; Péter Halász; Masahiko Watanabe; Miklós Palkovits; Zsófia Maglóczky; Tamás F Freund; István Katona
Journal:  J Neurosci       Date:  2008-03-19       Impact factor: 6.167

9.  Mediation of cannabidiol anti-inflammation in the retina by equilibrative nucleoside transporter and A2A adenosine receptor.

Authors:  Gregory I Liou; John A Auchampach; Cecilia J Hillard; Gu Zhu; Bilal Yousufzai; Salman Mian; Sohail Khan; Yousuf Khalifa
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-07-18       Impact factor: 4.799

10.  Basolateral amygdala regulation of adult hippocampal neurogenesis and fear-related activation of newborn neurons.

Authors:  E D Kirby; A R Friedman; D Covarrubias; C Ying; W G Sun; K A Goosens; R M Sapolsky; D Kaufer
Journal:  Mol Psychiatry       Date:  2011-06-14       Impact factor: 15.992

View more
  105 in total

Review 1.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

2.  Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal.

Authors:  Francisco Navarrete; Auxiliadora Aracil-Fernández; Jorge Manzanares
Journal:  Br J Pharmacol       Date:  2018-05-03       Impact factor: 8.739

Review 3.  CB2 Cannabinoid receptors as a therapeutic target-what does the future hold?

Authors:  Amey Dhopeshwarkar; Ken Mackie
Journal:  Mol Pharmacol       Date:  2014-08-08       Impact factor: 4.436

4.  Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea.

Authors:  Daniel I Brierley; James Samuels; Marnie Duncan; Benjamin J Whalley; Claire M Williams
Journal:  Psychopharmacology (Berl)       Date:  2015-10-06       Impact factor: 4.530

5.  Alterations in Gene and Protein Expression of Cannabinoid CB2 and GPR55 Receptors in the Dorsolateral Prefrontal Cortex of Suicide Victims.

Authors:  María S García-Gutiérrez; Francisco Navarrete; Gemma Navarro; Irene Reyes-Resina; Rafael Franco; Jose Luis Lanciego; Salvador Giner; Jorge Manzanares
Journal:  Neurotherapeutics       Date:  2018-07       Impact factor: 7.620

6.  Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine.

Authors:  J F C Pedrazzi; A C Issy; F V Gomes; F S Guimarães; E A Del-Bel
Journal:  Psychopharmacology (Berl)       Date:  2015-05-06       Impact factor: 4.530

Review 7.  Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol.

Authors:  Douglas L Boggs; Jacques D Nguyen; Daralyn Morgenson; Michael A Taffe; Mohini Ranganathan
Journal:  Neuropsychopharmacology       Date:  2017-09-06       Impact factor: 7.853

8.  Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1∆E9 mice.

Authors:  David Cheng; Jac Kee Low; Warren Logge; Brett Garner; Tim Karl
Journal:  Psychopharmacology (Berl)       Date:  2014-03-01       Impact factor: 4.530

Review 9.  Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids.

Authors:  Dennis J Sholler; Marilyn A Huestis; Benjamin Amendolara; Ryan Vandrey; Ziva D Cooper
Journal:  Pharmacol Biochem Behav       Date:  2020-10-18       Impact factor: 3.533

10.  Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor.

Authors:  R B Laprairie; A M Bagher; M E M Kelly; E M Denovan-Wright
Journal:  Br J Pharmacol       Date:  2015-10-13       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.